KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Receivables (2016 - 2025)

Historic Receivables for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $12.8 billion.

  • AbbVie's Receivables rose 1130.58% to $12.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $12.8 billion, marking a year-over-year increase of 1130.58%. This contributed to the annual value of $10.9 billion for FY2024, which is 211.56% down from last year.
  • Latest data reveals that AbbVie reported Receivables of $12.8 billion as of Q3 2025, which was up 1130.58% from $12.6 billion recorded in Q2 2025.
  • In the past 5 years, AbbVie's Receivables registered a high of $12.8 billion during Q3 2025, and its lowest value of $9.3 billion during Q3 2021.
  • Its 5-year average for Receivables is $11.2 billion, with a median of $11.3 billion in 2022.
  • As far as peak fluctuations go, AbbVie's Receivables surged by 5070.73% in 2021, and later plummeted by 211.56% in 2024.
  • Quarter analysis of 5 years shows AbbVie's Receivables stood at $10.0 billion in 2021, then increased by 12.8% to $11.3 billion in 2022, then fell by 0.88% to $11.2 billion in 2023, then fell by 2.12% to $10.9 billion in 2024, then rose by 16.94% to $12.8 billion in 2025.
  • Its last three reported values are $12.8 billion in Q3 2025, $12.6 billion for Q2 2025, and $12.5 billion during Q1 2025.